Cvaidmedical

CVAid Medical operates at the intersection of artificial intelligence, healthcare software, and medical devices, with a specific focus on stroke triage and care coordination. Its described approach combines smartphone-based data capture and specialized algorithms with workflows linking emergency medical services, emergency rooms, stroke centers, and physicians. CVA-Flow Connect adds a mobile and cloud-based tele-stroke component for virtual examination and communication. This scope distinguishes the company’s stated offering from a narrowly focused diagnostic tool: it aims to support multiple stages of the stroke-care journey, including pre-hospital assessment and post-discharge follow-up. The company raised a $4 million Series A in 2022, led by RAD BioMed Accelerator, with Philips and Sanara Ventures participating; it is listed as having 1–10 employees. These details indicate a small, focused company, but do not establish market share, clinical adoption, or regulatory status. The most visible potential differentiator is the combination of mobile assessment, AI-supported analysis, and cross-setting workflow coordination; evidence of outcomes or deployment scale is not documented.

CVAid Medical was founded in 2018 and its financing history shows one documented inflection point: a $4 million Series A announced on Feb 23, 2022. RAD BioMed Accelerator led the round, with Philips and Sanara Ventures among the participating investors. The company is listed with 1–10 employees and five current leadership positions, including founders covering executive, medical, scientific, and technical roles. Its product information identifies CVA-Flow Connect, a mobile and cloud-based tele-stroke system, while the company’s stated platform scope extends across pre-hospital assessment, hospital workflow management, and post-discharge follow-up. This combination suggests a development focus on connecting stroke assessment and care coordination rather than a single standalone application. Nor does it provide enough evidence to determine whether the 2022 financing led to broader clinical deployment or commercial growth. The trajectory therefore shows an early-stage company with a defined product direction and institutional investors, but its operating momentum after the Series A remains unclear.